



## Research Therapeutic Strategies for Alzheimer's Disease Treatments

Guest Editor:

### Dr. Santiago Grijalvo

1. Institute for Advanced  
Chemistry of Catalonia (IQAC-  
CSIC), Jordi Girona 18-26, E-  
08034 Barcelona, Spain

2. Networking Center on  
Bioengineering, Biomaterials and  
Nanomedicine (CIBER-BBN),  
Jordi Girona 18-26, E-08034  
Barcelona, Spain

Deadline for manuscript  
submissions:

**closed (30 June 2021)**

### Message from the Guest Editor

Dear Colleagues,

Alzheimer's disease is the most common form of dementia. AD is associated with the formation of  $\beta$ -amyloid plaques and neurofibrillary tangles in the brain. However, findings have shown that the accumulation of  $A\beta$  plaques is not sufficient to cause the disease. The acute inflammation may play a pivotal role in brain function, promoted by astrocytes activation and the production of proinflammatory markers. There is no effective therapeutic strategy that is capable of stopping or reverting the disease's progress because of the low drug solubility, rapid metabolism, or inability to cross the blood–brain barrier to reach brain parenchyma. Therefore, finding new therapies for treating Alzheimer's disease and other dementias remains a challenge.

Nanoparticles have displayed potential for encapsulating small molecule drugs, cross the blood–brain barrier, making nanomaterials a possibility for the treatment of Alzheimer's disease.

This Special Issue of the journal *Pharmaceutics* aims to improve our understanding of the therapeutic strategies of nanomaterials in the field of Alzheimer's disease and other dementias.





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Patrick J. Sinko**

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma